← All trials
NCT03223454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2017
- Primary completion
- Sep 30, 2019
- Completion date
- Mar 31, 2021
- First posted
- Jul 21, 2017
- Last posted
- Jul 21, 2017
- Enrollment
- 50
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chongqing Medical UniversityLead sponsor
- Chongqing Medical UniversityOverall official - principal investigator
- Chongqing Medical UniversityStudy chair
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.